On May 15, 2025, Opus Genetics, Inc. announced its financial results for the first quarter ended March 31, 2025. The company reported license and collaborations revenue of $4.4 million, a significant increase from $1.7 million in the first quarter of 2024.
The net loss for the quarter was $8.2 million, or $(0.24) per basic and diluted share, compared to a net loss of $7.1 million, or $(0.29) per share, for the same period in 2024. Research and development expenses increased to $8.0 million from $4.7 million in the prior year, primarily due to higher clinical costs and payroll.
As of March 31, 2025, Opus Genetics held $41.8 million in cash and cash equivalents. Management projects this liquidity will be sufficient to fund operations into the second quarter of 2026, supporting the advancement of its inherited retinal disease platform and phentolamine eye drop franchise.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.